BeyondSpring Inc.

BeyondSpring Inc. is a clinical-stage global biopharmaceutical company focused on developing innovative therapies for patients with high unmet medical needs, primarily in oncology. The company's core business model revolves around the development and potential commercialization of its lead asset, Plinabulin, and a pipeline of small molecule immune agents, as well as an equity stake in SEED Therapeutics Inc., which utilizes a proprietary Targeted Protein Degradation (TPD) drug discovery platform. Revenue generation is currently through collaboration arrangements and the sale of subsidiary interests, as the company has no products approved for commercial sale and has not generated any revenue from product sales to date ¹. The primary customer segments for its potential products are cancer patients, particularly those with non-small cell lung cancer (NSCLC) and those at risk of chemotherapy-induced neutropenia (CIN).

Plinabulin, the company's first-in-class lead asset, is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanisms. It is being developed as a potential "pipeline in a drug" for various cancer indications as a direct anti-cancer agent, with the added safety benefit of reducing CIN. Plinabulin has been administered to over 700 cancer patients with generally good tolerability ². The company is also developing three small molecule immune agents, BPI-002, BPI-003, and BPI-004, which are currently in preclinical stages ³. BPI-002 is an oral small molecule agent that increases T-cell co-stimulation, BPI-003 is a novel small molecule inhibitor of IKK, and BPI-004 induces the production of neo-antigens by tumor cells ⁴.

A significant product line is Plinabulin for the treatment of advanced and metastatic NSCLC. The DUBLIN-3 Phase 3 study, which enrolled 559 patients globally, demonstrated that the Plinabulin and docetaxel combination had statistically significant and clinically meaningful overall survival benefit compared to docetaxel alone, with doubling 2-year and 3-year OS rates ⁵. It also showed an 82% relative reduction in grade 4 neutropenia in Cycle 1 Day 8 (p<0.0001) ⁶. The median OS in the Plinabulin/docetaxel arm was 11.4 months versus 8.8 months in the docetaxel arm for the non-squamous subset (OS HR 0.72, p=0.0078) ⁷.

Another key product line is Plinabulin for the prevention of CIN. The PROTECTIVE-2 Phase 3 study, a registration superiority study, demonstrated that Plinabulin in combination with pegfilgrastim showed superior CIN prevention benefit compared to pegfilgrastim alone. The study met its primary endpoint with a statistically significant improvement in the rate of prevention of grade 4 neutropenia, increasing from 13.6% to 31.5% (p=0.0015) ⁸. It also met key secondary endpoints, including mean ANC Nadir of 0.538 x 10^9 cells/L (p=0.0002) and a rate of prevention of grade 3 neutropenia of 20.7% versus 4.6% (p=0.003) ⁹. However, the FDA issued a Complete Response Letter in November 2021, indicating that the results were not sufficiently robust and a second well-controlled trial would be required ¹⁰. The NDA submission for this indication was withdrawn from the NMPA in March 2023 ¹¹.

The company also holds an equity stake in SEED Therapeutics Inc., which is utilizing a proprietary Targeted Protein Degradation (TPD) drug discovery platform. SEED's wholly owned lead oncology asset, a novel RBM39 degrader (ST-01156), entered Phase 1 clinical studies in January 2026 ¹². SEED has collaborations with Eli Lilly and Eisai to discover and develop new chemical entities through this TPD platform, with potential milestone payments of up to approximately $780 million from Eli Lilly and up to $1.5 billion from Eisai ¹³. As of December 31, 2025, the BYSI Entities own approximately 38.03% of the outstanding equity interest in SEED ¹⁴.

For the fiscal year ended December 31, 2025, the company reported a consolidated net loss of $14.2 million ¹⁵, compared to a net loss of $16.7 million for the year ended December 31, 2024 ¹⁶. The accumulated deficit as of December 31, 2025, was $408.4 million ¹⁷, up from $407.4 million as of December 31, 2024 ¹⁸. Net cash used for operating activities was $19.8 million for the year ended December 31, 2025 ¹⁹, compared to $16.4 million for the year ended December 31, 2024 ²⁰. Cash and cash equivalents for continuing operations were $7.8 million at December 31, 2025 ²¹, compared to $2.9 million at December 31, 2024 ²². Short-term investments for continuing operations were $4.8 million at December 31, 2025, compared to nil at December 31, 2024 ²³. The filing does not provide specific figures for total revenue, gross profit, gross margin percentage, operating income, operating margin, diluted EPS, free cash flow, total debt, or net debt for the reported fiscal period.

During the reported period, SEED's lead oncology asset, ST-01156, a novel RBM39 degrader, entered Phase 1 clinical studies in January 2026 ²⁴. The IND application for ST-01156 was cleared by the FDA in August 2025 and by the NMPA in November 2025 ²⁵. In September 2025, SEED completed the second close of its Series A-3 financing, selling an aggregate of 1,411,761 Series A-3 Preferred Shares for an aggregate purchase price of $6.0 million ²⁶. In January 2025, the company entered into agreements to sell a portion of its Series A-1 Preferred Shares of SEED for $35.4 million, or $4.25 per share, in three installments, with the first closing of approximately $7.35 million occurring in February 2025 ²⁷. The DUBLIN-3 study results were published in LANCET Respiratory Medicine journal in September 2024 ²⁸.

The company plans to use its best efforts to file an NDA with the NMPA as soon as possible for the Plinabulin regimen in second- and third-line NSCLC with EGFR wild type, based on the positive results from the DUBLIN-3 study ²⁹. The company is also evaluating the feasibility of filing NDAs with regulatory agencies of other jurisdictions ³⁰. Furthermore, a confirmatory global Phase 3 study in second- and third-line non-squamous NSCLC with epidermal growth factor receptor (EGFR) wild type after progression on prior immune checkpoint inhibitors is planned, following productive discussions with the US regulatory agency ³¹.

A major growth area is the continued development of Plinabulin as a potential "pipeline in a drug" in multiple solid tumor cancer indications, particularly in combination with immuno-oncology agents and other synergistic standards of care to address severe unmet medical needs in oncology ³². The company believes Plinabulin's unique mechanism, involving dendritic cell maturation and T-cell activation, and tumor vasculature modulation, supports improved anti-cancer efficacy in combination with tumor antigen generators, including chemotherapy or radiation, with or without checkpoint inhibitors ³³. Multiple ongoing investigator-initiated studies with PD-1 antibodies are being conducted at leading institutions, with the goal of advancing Plinabulin in clinical trials as an immuno-oncology agent, especially in PD-1/PD-L1 antibody progressed patients ³⁴.

Another significant growth area is maximizing the value of SEED's Targeted Protein Degradation (TPD) technology platform ³⁵. SEED's lead candidate, ST-01156, a brain-penetrant RBM39 degrader, has entered clinical development for Ewing sarcoma and other RBM39-dependent cancers, with Orphan Drug and Rare Pediatric Disease designations from the FDA for Ewing sarcoma ³⁶. The IND application for ST-01156 was cleared by the FDA in August 2025 and by the NMPA in November 2025, and the first patient was dosed in the Phase 1a dose-escalation study in January 2026 ³⁷. SEED has collaborations with Eli Lilly and Eisai to discover and develop novel chemical entities through this TPD platform, with potential preclinical, clinical, regulatory, and commercial milestones of up to approximately $780 million from Eli Lilly and up to $1.5 billion from Eisai ³⁸. SEED's pipeline includes six internal projects and three joint development programs, targeting oncology, neurodegeneration, immunology, and antiviral indications, with additional programs in development for anti-aging applications ³⁹.

The company expects to continue to incur significant and increasing operating losses and negative cash flows for the foreseeable future due to substantial research and development expenses related to ongoing and planned clinical trials ⁴⁰. The company will need to obtain additional financing to fund future operations, including conducting additional clinical trials that may be required by the FDA for CIN prevention and to support a potential NDA filing for NSCLC, as well as to complete the development and commercialization of future product candidates ⁴¹. The second closing of approximately $13.19 million from the sale of SEED Series A-1 Preferred Shares is expected in 2026, and the third closing of approximately $14.88 million is scheduled to occur no later than December 15, 2026 ⁴².

The company plans to seek a co-development and commercialization partner for Plinabulin in the U.S. and the rest of the world to maximize its potential in multiple cancer indications, if approved ⁴³. This strategy is driven by the belief that Plinabulin's opportunities surpass the company's current resources ⁴⁴.

The company's strategies around Plinabulin are dependent upon its ability to obtain additional funding ⁴⁵. General market conditions and the Complete Response Letter received from the FDA have caused and may continue to cause difficulties in seeking financing from capital markets ⁴⁶. The company may not be able to complete financing on reasonable terms or at all, which could force delays, reductions, or elimination of research and development programs or future commercialization efforts ⁴⁷. The ongoing hostilities between Russia and Ukraine may require the company to avoid conducting any future clinical trials in such jurisdictions due to difficulties in enrolling patients and supply chain disruptions, although no clinical trials are currently planned there ⁴⁸.

The company faces significant financial risks, having incurred net losses in each period since inception, with a consolidated net loss of $14.2 million for 2025 and an accumulated deficit of $408.4 million as of December 31, 2025 ⁴⁹. Substantial additional financing will be required to fund future operations, including clinical trials and commercialization, and the inability to obtain such financing could lead to delays or termination of development programs ⁵⁰. Clinical development of Plinabulin is highly uncertain; the FDA's Complete Response Letter for CIN prevention, requiring a second well-controlled trial, highlights the risk of delays or failure to obtain regulatory approval ⁵¹. The company's reliance on a single lead asset, Plinabulin, for multiple indications means that failure in its development would materially harm the business ⁵². Regulatory approval processes are lengthy and unpredictable, with risks including disagreement with regulators on trial design, failure to demonstrate safety and efficacy, and the potential for additional studies, particularly given that a majority of patients in the DUBLIN-3 NSCLC trial (approximately 87%) were in China, which may raise concerns about applicability to the U.S. patient population ⁵³. Commercialization risks include failure to achieve market acceptance, inability to establish effective sales and marketing capabilities, and intense competition from larger pharmaceutical companies with greater resources ⁵⁴. Intellectual property risks include the possibility that pending patent applications may not issue, issued patents may be challenged or circumvented, and the difficulty of enforcing patent rights globally ⁵⁵. The company relies heavily on third-party CROs and manufacturers, and their failure to comply with regulations, meet deadlines, or provide sufficient quantities or quality of product could severely disrupt operations ⁵⁶. Specifically, the company relies on BASF SE as the sole supplier of Kolliphor HS15, a stabilizing agent for Plinabulin, and its unavailability would require reformulation and cause significant delays ⁵⁷. International operations expose the company to risks such as unexpected legislative changes, economic instability, and difficulties in enforcing contractual provisions ⁵⁸. Compliance with U.S. federal and state anti-kickback, false claims, and data privacy laws, as well as Chinese regulations on human genetic resources and data security, poses significant legal and financial risks ⁵⁹.

Management emphasizes the company's focus as a clinical-stage global biopharmaceutical company dedicated to developing innovative therapies for high unmet medical needs, particularly in oncology. A key strategic priority is the development of Plinabulin as a "pipeline in a drug" in multiple solid tumor cancer indications, exploring its potential in combination with immuno-oncology agents and other synergistic standards of care ⁶⁰. Management highlights Plinabulin's unique mechanism, involving dendritic cell maturation and T-cell activation, and tumor vasculature modulation, as supporting its improved anti-cancer efficacy ⁶¹. The company is committed to advancing Plinabulin through global clinical trials and obtaining regulatory approvals, specifically noting plans to use best efforts to file an NDA with the NMPA for second- and third-line non-squamous EGFR wild type NSCLC as soon as possible, and to initiate a confirmatory global Phase 3 study for this indication based on discussions with the US regulatory agency ⁶². Another strategic priority is to maximize the value of SEED's Targeted Protein Degradation (TPD) technology platform, citing ongoing collaborations with Eli Lilly and Eisai as validation of the platform's potential and the team's execution capabilities ⁶³. Management also acknowledges the need for additional funding to support the execution of its business plan and to maximize shareholder value, exploring strategic options such as licensing, partnerships, asset sales, or equity/debt financing ⁶⁴. The company's overall tone suggests a strong belief in the scientific merit and commercial potential of its pipeline, while also recognizing the significant financial and regulatory challenges inherent in the biopharmaceutical industry.